SFM
ALXN

Sphera Funds Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Sphera Funds Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-60,000
Closed -$9.37M – 212
2020
Q4 		$9.37M Buy
+60,000
New +$7.71M 0.83% 33
2020
Q2 		– Sell
-249,396
Closed -$22.4M – 116
2020
Q1 		$22.4M Buy
249,396
+133,683
+116% +$13.1M 2.8% 11
2019
Q4 		$12.5M Sell
115,713
-50,000
-30% -$5.35M 1.03% 16
2019
Q3 		$16.2M Sell
165,713
-171,087
-51% -$19.3M 2.51% 10
2019
Q2 		$44.1M Buy
336,800
+89,500
+36% +$11.5M 6.03% 2
2019
Q1 		$33.4M Buy
247,300
+79,200
+47% +$9.85M 3.05% 5
2018
Q4 		$16.4M Buy
168,100
+26,400
+19% +$3.12M 1.84% 13
2018
Q3 		$19.7M Sell
141,700
-18,844
-12% -$2.36M 2.26% 9
2018
Q2 		$19.9M Buy
160,544
+78,544
+96% +$9.18M 2.75% 8
2018
Q1 		$9.14M Sell
82,000
-38,000
-32% -$4.54M 1.39% 18
2017
Q4 		$14.4M Buy
+120,000
New +$14.6M 1.68% 10
2017
Q3 		– Sell
-100,000
Closed -$12.2M – 156
2017
Q2 		$12.2M Buy
+100,000
New +$11.6M 2.07% 13
2017
Q1 		– Sell
-113,000
Closed -$13.8M – 130
2016
Q4 		$13.8M Buy
113,000
+43,000
+61% +$5.26M 3.5% 6
2016
Q3 		$8.58M Buy
70,000
+27,677
+65% +$3.56M 1.4% 16
2016
Q2 		$4.94M Buy
42,323
+2,323
+6% +$330K 1.28% 19
2016
Q1 		$5.57M Sell
40,000
-19,164
-32% -$2.81M 1.21% 13
2015
Q4 		$11.3M Buy
59,164
+24,164
+69% +$4.22M 1.65% 12
2015
Q3 		$5.47M Buy
+35,000
New +$6.38M 0.7% 30
2015
Q2 		– Sell
-25,000
Closed -$4.33M – 168
2015
Q1 		$4.33M Buy
+25,000
New +$4.53M 0.45% 54

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sphera Funds Management's ALXN Position: Q1 2021 in Review

Sphera Funds Management sold out of Alexion Pharmaceuticals (ALXN) in Q1 2021, closing a stake of 60,000 shares — an estimated $9.37M sold.

Sphera Funds Management first reported a position in ALXN in Q1 2015 and held it in 19 quarters. The position peaked at $44.1M in Q2 2019. 753 funds tracked by Wall St. Rank hold ALXN as of Q1 2021.

  • Sphera Funds Management reported no remaining Alexion Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Sphera Funds Management sold 60,000 Alexion Pharmaceuticals shares in Q1 2021, an estimated $9.37M.
  • Sphera Funds Management first reported a position in Alexion Pharmaceuticals in Q1 2015 and held it in 19 quarters.
  • Sphera Funds Management's Alexion Pharmaceuticals position peaked at $44.1M in Q2 2019.
  • 753 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2021.

Based on Sphera Funds Management's 13F filing for Q1 2021, filed 17 May 2021.